Skip to main content
logo
Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
12.94
-0.33 (-2.49%)
At close: Oct 31, 2025, 4:00 PM EDT
12.95
+0.01 (0.08%)
After-hours: Oct 31, 2025, 6:43 PM EDT

Company Description

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States.

The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo.

Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Forte Biosciences, Inc.
Forte Biosciences logo
CountryUnited States
IndustryBiotechnology
SectorHealthcare
Employees14
CEOPaul A. Wagner

Contact Details

Address:
3060 Pegasus Park Drive, Building 6
Dallas, Texas 75247
United States
Phone310 618 6994
Websitefortebiorx.com

Stock Details

Ticker SymbolFBRX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001419041
CUSIP Number34962G109
ISIN NumberUS34962G2084
Employer ID26-1243872
SIC Code2834

Key Executives

NamePosition
Dr. Paul A. Wagner Ph.D.Chief Executive Officer, President and Chairman
Antony A. Riley CPAChief Financial Officer
Dr. Barbara K. Finck M.D.Chief Medical Clinician and Director
Christopher RoenfeldtChief Operating Officer

Latest SEC Filings

DateTypeTitle
Oct 7, 2025SCHEDULE 13G/AFiling
Sep 30, 2025S-8Securities to be offered to employees in employee benefit plans
Sep 5, 2025SCHEDULE 13G/AFiling
Aug 14, 2025SCHEDULE 13G/AFiling
Aug 14, 2025SCHEDULE 13G/AFiling
Aug 14, 202510-QQuarterly Report
Aug 14, 20258-KCurrent Report
Aug 14, 2025SCHEDULE 13G/AFiling
Aug 7, 2025SCHEDULE 13G/AFiling
Aug 4, 2025SCHEDULE 13G/AFiling
View All SEC Filings